Medicaid GLP-1 Coverage by State
Last checked against KFF's January 2026 survey
Sources last checked September 21, 2026
This applies to obesity/weight-loss coverage specifically. GLP-1s prescribed for type 2 diabetes are covered by every state Medicaid program regardless of what's below — that coverage is federally required, not optional.
States covering GLP-1s for obesity (fee-for-service)
KFF, "Medicaid Coverage of and Spending on GLP-1s", January 2026
KFF, "Medicaid Coverage of and Spending on GLP-1s", January 2026
KFF, "Medicaid Coverage of and Spending on GLP-1s", January 2026
North Carolina temporarily dropped coverage in October 2025 and reinstated it in December 2025 — its current status above reflects January 2026.
States that dropped coverage in 2026
KFF, "Medicaid Coverage of and Spending on GLP-1s", January 2026
KFF, "Medicaid Coverage of and Spending on GLP-1s", January 2026
KFF, "Medicaid Coverage of and Spending on GLP-1s", January 2026
What to know before you assume either way
- Even in covering states, expect prior authorization, BMI thresholds, and documentation of prior weight-loss attempts.
- Managed-care plans within a state can differ from the fee-for-service policy listed here.
- The CMS BALANCE Model is a voluntary federal program that could let more state Medicaid agencies add coverage at negotiated prices, with applications open through July 2026 and coverage potentially starting in 2027.
- Compounded semaglutide/tirzepatide is not covered by Medicaid in any state — it's cash-pay only.
See cash-pay and telehealth options that don't depend on your state Medicaid policy.
See Cash-Pay Options →Source: KFF, "Medicaid Coverage of and Spending on GLP-1s", January 2026 fee-for-service survey. Coverage changes quarterly — confirm current status with your state Medicaid office before relying on this page.